title: The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies.
abstract: OBJECTIVE
  To compare the rates of gestational diabetes among women who received serial doses of 17-alpha hydroxyprogesterone caproate vs placebo.
  
  
  METHODS
  Secondary analysis of 2 double-blind randomized placebo-controlled trials of 17-alpha hydroxyprogesterone caproate given to women at risk for preterm delivery. The incidence of gestational diabetes was compared between women who received 17-alpha hydroxyprogesterone caproate or placebo.
  
  
  RESULTS
  We included 1094 women; 441 had singleton and 653 had twin gestations. Combining the 2 studies, 616 received 17-alpha hydroxyprogesterone caproate and 478 received placebo. Among singleton and twin pregnancies, rates of gestational diabetes were similar in women receiving 17-alpha hydroxyprogesterone caproate vs placebo (5.8% vs 4.7%; P = .64 and 7.4% vs 7.6%; P = .94, respectively). In the multivariable model, progesterone was not associated with gestational diabetes (adjusted odds ratio, 1.04; 95% confidence interval, 0.62-1.73).
  
  
  CONCLUSIONS
  Weekly administration of 17-alpha hydroxyprogesterone caproate is not associated with higher rates of gestational diabetes in either singleton or twin pregnancies.
authors.affiliation: Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
authors.forename: Cynthia
authors.initials: C
authors.lastname: Gyamfi
authors.forename: Amanda L
authors.initials: AL
authors.lastname: Horton
authors.forename: Valerija
authors.initials: V
authors.lastname: Momirova
authors.forename: Dwight J
authors.initials: DJ
authors.lastname: Rouse
authors.forename: Steve N
authors.initials: SN
authors.lastname: Caritis
authors.forename: Alan M
authors.initials: AM
authors.lastname: Peaceman
authors.forename: Anthony
authors.initials: A
authors.lastname: Sciscione
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Meis
authors.forename: Catherine Y
authors.initials: CY
authors.lastname: Spong
authors.forename: Mitchell
authors.initials: M
authors.lastname: Dombrowski
authors.forename: Baha
authors.initials: B
authors.lastname: Sibai
authors.forename: Michael W
authors.initials: MW
authors.lastname: Varner
authors.forename: Jay D
authors.initials: JD
authors.lastname: Iams
authors.forename: Brian M
authors.initials: BM
authors.lastname: Mercer
authors.forename: Marshall W
authors.initials: MW
authors.lastname: Carpenter
authors.forename: Julie
authors.initials: J
authors.lastname: Lo
authors.forename: Susan M
authors.initials: SM
authors.lastname: Ramin
authors.forename: Mary Jo
authors.initials: MJ
authors.lastname: O'Sullivan
authors.forename: Menachem
authors.initials: M
authors.lastname: Miodovnik
authors.forename: Deborah
authors.initials: D
authors.lastname: Conway
mesh_terms: D000077713:17 alpha-Hydroxyprogesterone Caproate; D016640:Diabetes, Gestational / Q000453:epidemiology*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006908:Hydroxyprogesterones / Q000627:therapeutic use*; D015999:Multivariate Analysis; D011247:Pregnancy; D011272:Pregnancy, Multiple; D011372:Progestins / Q000627:therapeutic use*; D012307:Risk Factors
chemical_list: D006908:Hydroxyprogesterones; D011372:Progestins; D000077713:17 alpha-Hydroxyprogesterone Caproate